Pharmaceuticals
Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai
TOKYO, Feb. 3, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.39 billion (USD 8.8 million1) in six R&D projects for the development of drugs, diagnostics and vaccines for malaria, tuberculosis (TB), and neglected ...
2026-02-03 09:00
3702
NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Begin Trading on NYSE in Record Transfer
NEW YORK, Feb. 2, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Beg...
2026-02-02 22:39
8148
DHL Health Logistics Singapore Expands Capabilities to Elevate Life Science & Healthcare Logistics
Strategic expansion positions Singapore as a strategic arm for healthcare logistics in the APAC region. * DHL Group invests €10 million in a new pharmaceutical hub in Singapore to enhance international logistics and healthcare logistics infrastructure across the Asia-Pacific region. * The ex...
2026-02-02 10:00
4602
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Adult Type 2 Diabetes
HANGZHOU, China, Jan. 30, 2026 /PRNewswire/ -- Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has approved ...
2026-01-30 19:54
5731
Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao
BOAO, China, Jan. 29, 2026 /PRNewswire/ -- The International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital. Established through a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, this center tackle...
2026-01-29 20:00
3833
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial couple...
2026-01-29 19:00
4674
NYSE Content Advisory: Pre-Market Update + First Lady Melania Trump to Ring NYSE Bell for Doc 'Melania'
NEW YORK, Jan. 28, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + First Lady Melania Tr...
2026-01-28 21:55
6979
Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications
HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Con...
2026-01-28 19:39
4092
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
The US Food and Drug Administration (FDA) has approved Novo Nordisk's new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from base...
2026-01-28 10:45
5424
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based on propensity score weighting. Skyhawk also ann...
2026-01-27 21:00
4668
Libevitug Approved in China as First-in-Class Hepatitis D Treatment
BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a hum...
2026-01-27 16:15
4575
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
* Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. * Growth over the financial year was driven by increased sales in oncology, particularly in the United States. * Several partnership agreements in oncology and neurology strengthen the Group's R&D portfoli...
2026-01-27 16:00
4113
Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease
SHANGHAI, Jan. 27, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® (ensifentrine) for the maintenance treatment of chronic obstructive p...
2026-01-27 10:13
3876
Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology
SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbenitamab injection (KN026), independently developed by the ...
2026-01-27 09:58
4373
Gu Sheng Tang Donates S$1.06 Million to NTU Singapore to Advance Traditional Chinese Medicine Research and Education in Singapore
SINGAPORE, Jan. 26, 2026 /PRNewswire/ -- Leading Traditional Chinese Medicine (TCM) healthcare group Gu Sheng Tang TCM and Nanyang Technological University, Singapore (NTU Singapore) officially launched theGu Sheng Tang Traditional Chinese Medicine Education and Research Programme today. As part ...
2026-01-26 18:00
4153
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and auto...
2026-01-26 17:35
10699
Get Exclusive Limited-Edition Gifts During Your Lunar New Year Trip: Wakamoto Launches "Thank You from Wakamoto" Campaign
TOKYO, Jan. 26, 2026 /PRNewswire/ -- Wakamoto Pharmaceutical Co., Ltd. (Tokyo,
Arata Igarashi), a company dedicated to supporting healthy and active
lifestyles, will launch a nationwide campaign in which customers who purchase
"Strong Wakamoto" will receive an original hand towel.
2026-01-26 13:00
4205
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
-Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026. -ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or o verweight, withbetter gastrointestina...
2026-01-26 08:10
6050
Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard
TIANJIN, China, Jan. 26, 2026 /PRNewswire/ -- In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal Stromal Cells (MSCs) was accepted by the U.S. Food and Drug Administration (FDA). The agency's Master ...
2026-01-26 08:00
5171
Telangana (India) Sets Global Ambition with Next-Gen Life Sciences Policy 2026-30
* Positioning Telangana among the world's top five life sciences clusters by 2030 * Targets USD 25 billion in investments * Shifts focus from scale-led manufacturing to innovation-driven, value creation DAVOS, Switzerland, Jan. 22, 2026 /PRNewswire/ -- The Government of Telangana, India tod...
2026-01-22 09:00
5273
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 298 media titles]
2026-02-10 13:31Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
[Picked up by 298 media titles]
2026-02-09 10:00
Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
2026-02-09 10:00
8061
AIA RESEARCH REVEALS INGRAINED HEALTH STEREOTYPES ARE HOLDING BACK WELLBEING IN ASIA
2026-02-09 16:08
6443
Aon and KNIAZHA VIENNA INSURANCE GROUP announce new $25M war-risk insurance facility with the U.S. International Development Finance Corporation
2026-02-09 22:42
6290
Agoda Launches Free Global eSIMs for VIP Diamond Members
2026-02-10 14:00
5800
